vendredi 2 décembre 2016

Onco Actu du 2 décembre 2016

1. Biologie

Why Testicular Tumors Are So Vulnerable to Getting Hit with Chemo [GEN]

2. Etiologie

Why disrupted body clocks trigger liver cancer [The Economist]

2.10 Etiologie - Alcool

Alcohol Intake Associated with Increased Risk of Melanoma [AACR]

3.1 Tabac

On the pleasure of smoking [The Conversation]

BAT Bets on Vaping as Tobacco Makers Do Battle With New Devices [Bloomberg]

3.7 Alcool

Minimum alcohol pricing gets backing of UK government's health advisers [The Guardian]

4. Dépistage, diagnostic et pronostic

Next Generation: Observing Cancer-Associated Mitochondrial Changes [The Scientist]

4.12 Biopsies liquides

GRAIL Announces Circulating Cell-free Genome Atlas (CCGA) Study as Foundation for Development of Blood Test to Detect Cancer Early [Grail]

5. Traitements

Novel Akt inhibitor ipatasertib evidenced as a promising contender for therapy against solid tumors [VHIO]

Research says: Patients with cancer history experiencing severe heart attacks benefit from cardiac treatment [Mayo Clinic]

5.10 Traitements - Essais

Niraparib Maintenance Therapy in Ovarian Cancer [Now@NEJM]

5.12 Immunothérapies

A disruptive billionaire with a yen for innovation herds top researchers into a neoantigen cancer coalition [EndPoints]

5.12.2 Immunothérapies - CAR-T

Bluebird, Celgene jump off to a promising start in the marathon race to develop a CAR-T for multiple myeloma [EndPoints]

5.2 Pharma

FDA Grants Priority Review to Supplemental Biologics License Application (sBLA) for Merck’s KEYTRUDA® (pembrolizumab) in Relapsed or Refractory Classical Hodgkin Lymphoma [Merck]

5.2.1 Pharma - Partenariats

IBM unveils Watson for drug R&D, teams with Pfizer on oncology [FierceBiotech]

AstraZeneca in broad drug deal with Bicycle worth up to $1 bln [Reuters]

5.2.3 Pharma - économie

Round 2 in Boehringer’s US reorganization will claim another 244 jobs, including small molecule group [EndPoints]

5.3 Traitements - FDA, EMA, NICE...

Workshop on adaptive pathways – discussion on development approach for medicines addressing unmet medical needs [EMA]

Simpler website navigation for regulatory information on human medicines [EMA]

Cancer drugs may remain approved despite lack of benefit [Reuters]

5.4 Traitements - Economie

NICE recommends new lung cancer drug pembrolizumab [NICE]

Merck wins UK okay for Keytruda in lung cancer after price cut [Reuters]

5.9.4 ENA

EORTC-NCI-AACR 2016: Liquid Biopsies Identify Molecular Alterations Driving GI Cancer Drug Resistance in Nearly 80% of Patients [ASCO Post]

Phase I trial shows that a drug that inhibits the Notch signalling process is active in a range of advanced cancers [ECCO]

Advanced soft tissue sarcomas respond to a combination of a new and an existing anti-cancer drug [ECCO]

6.10.1 Politiques (USA)

21st Century Cures Act will distort the meaning of ‘FDA approved’ [STAT]

21st Century Cures Act supporters crush meager House opposition, head to a final showdown in the Senate [EndPoints]

Maryland congressman in running to head NIH? [Science]

US health-reform legislation clears big hurdle [Nature]

6.11 Patients

More research volunteers are getting their medical test results. Should we cheer — or worry? [STAT]